These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 35184426)

  • 21. Association Between Gut Microbiota and Elevated Serum Urate in Two Independent Cohorts.
    Wei J; Zhang Y; Dalbeth N; Terkeltaub R; Yang T; Wang Y; Yang Z; Li J; Wu Z; Zeng C; Lei G
    Arthritis Rheumatol; 2022 Apr; 74(4):682-691. PubMed ID: 34725964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Wang LM; Wang P; Teka T; Zhang YC; Yang WZ; Zhang Y; Wang T; Liu LX; Han LF; Liu CX
    J Agric Food Chem; 2020 Nov; 68(47):14059-14070. PubMed ID: 33146009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Uric acid-lowering effect of dotinurad, a novel selective urate reabsorption inhibitor, in hypertensive patients with gout or asymptomatic hyperuricemia: a pooled analysis of individual participant data in phase II and III trials.
    Takahashi T; Beppu T; Hidaka Y; Hosoya T
    Clin Exp Hypertens; 2021 Nov; 43(8):730-741. PubMed ID: 34425059
    [No Abstract]   [Full Text] [Related]  

  • 25. Effect of Urate-Lowering Therapy on All-Cause and Cardiovascular Mortality in Hyperuricemic Patients without Gout: A Case-Matched Cohort Study.
    Chen JH; Lan JL; Cheng CF; Liang WM; Lin HY; Tsay GJ; Yeh WT; Pan WH
    PLoS One; 2015; 10(12):e0145193. PubMed ID: 26683302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan.
    Koto R; Nakajima A; Horiuchi H; Yamanaka H
    Ann Rheum Dis; 2021 Nov; 80(11):1483-1490. PubMed ID: 34158371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How should we manage asymptomatic hyperuricemia?
    Chalès G
    Joint Bone Spine; 2019 Jul; 86(4):437-443. PubMed ID: 30316974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016.
    Chen-Xu M; Yokose C; Rai SK; Pillinger MH; Choi HK
    Arthritis Rheumatol; 2019 Jun; 71(6):991-999. PubMed ID: 30618180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of gut microbiota in gout: Is gut microbiota a potential target for gout treatment.
    Tong S; Zhang P; Cheng Q; Chen M; Chen X; Wang Z; Lu X; Wu H
    Front Cell Infect Microbiol; 2022; 12():1051682. PubMed ID: 36506033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristic dysbiosis in gout and the impact of a uric acid-lowering treatment, febuxostat on the gut microbiota.
    Lin S; Zhang T; Zhu L; Pang K; Lu S; Liao X; Ying S; Zhu L; Xu X; Wu J; Wang X
    J Genet Genomics; 2021 Sep; 48(9):781-791. PubMed ID: 34509383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gout, urate-lowering therapy, and uric acid levels among adults in the United States.
    Juraschek SP; Kovell LC; Miller ER; Gelber AC
    Arthritis Care Res (Hoboken); 2015 Apr; 67(4):588-92. PubMed ID: 25201123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrated network pharmacology and gut microbiome analysis to reveal the mechanism of Qu-Zhuo-Tong-Bi decoction against hyperuricemia and gout.
    Song S; Fan M; Wen X; Shi X; Lou Y; He Z; Wen C; Shao T
    J Ethnopharmacol; 2023 Nov; 316():116736. PubMed ID: 37286117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Discontinuation of Urate-Lowering Therapy: A Systematic Review.
    Beslon V; Moreau P; Maruani A; Maisonneuve H; Giraudeau B; Fournier JP
    J Gen Intern Med; 2018 Mar; 33(3):358-366. PubMed ID: 29204974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Knowledge and practice in the management of asymptomatic hyperuricemia among primary health care physicians in Jeddah, Western Region of Saudi Arabia.
    Alqarni NA; Hassan AH
    Saudi Med J; 2018 Dec; 39(12):1218-1225. PubMed ID: 30520504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Gout and cardiovascular risk].
    Němec P
    Vnitr Lek; 2014 Oct; 60(10):893-901. PubMed ID: 25382012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
    Wortmann RL; Macdonald PA; Hunt B; Jackson RL
    Clin Ther; 2010 Dec; 32(14):2386-97. PubMed ID: 21353107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Isolation and identification of uric acid-dependent
    Liu W; Nan F; Liu F; Yang X; Li Z; Jiang S; Zhang X; Li J; Yu M; Wang Y; Wang B
    mSphere; 2024 Jun; 9(6):e0002524. PubMed ID: 38814072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urate-lowering Therapy and Chronic Kidney Disease Development in Patients with Gout.
    Yen FS; Wei JC; Chang CL; Yang CC; Hsu CC; Hwu CM
    Int J Med Sci; 2021; 18(12):2599-2606. PubMed ID: 34104091
    [No Abstract]   [Full Text] [Related]  

  • 39. Debates in gout management.
    Abhishek A
    Curr Opin Rheumatol; 2020 Mar; 32(2):134-139. PubMed ID: 31842034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacist-managed titration of urate-lowering therapy to streamline gout management.
    Huang IJ; Liew JW; Morcos MB; Zuo S; Crawford C; Bays AM
    Rheumatol Int; 2019 Sep; 39(9):1637-1641. PubMed ID: 31147732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.